Keywords: India, Rheumatoid arthritis, Market, Simponi, Biologicals
India's rheumatoid arthritis drug market will more than double by 2013
Article | 14 October 2009
The rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013, according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
